Armetheon Inc Report issue

For profit Phase 3
Founded: Menlo Park CA United States (2011)
Status: Acquired by Espero BioPharma (2017)

Organization Overview

First Clinical Trial
2016
NCT02522221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

tecarfarin (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thromboembolism (Phase 3)

Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2